Merck, a leading science and technology company, announced that it has signed a license agreement providing Evotec SE access to Merck’s foundational CRISPR intellectual property. Evotec, an international biotechnology company headquartered in Hamburg, Germany, will use Merck’s CRISPR genome-editing technology to create edited cell lines for Evotec’s commercial and internal research purposes.
“This CRISPR license is the impetus for important drug testing and discovery that promises to accelerate research and lead to the development of new therapies,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science. “Merck has been at the forefront of innovation in gene editing for 15 years and continues to work with industry and academia to solve complex problems using our patented CRISPR technology, both ethically and responsibly.”